Compare Enveric Biosciences Inc (ENVB) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Johnson Controls International PLC — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Johnson Controls International PLC trades at $157.44 (market cap $93.28B). The key difference: Johnson Controls International PLC is far larger — about 13717.6× Enveric Biosciences Inc's market cap, and Johnson Controls International PLC pays a 1.04% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Johnson Controls International PLC for 65 Days on average.
| ENVB | JCI | |
|---|---|---|
Market Cap | $6.80M | $93.28B |
Volume | 64,867 | 2,786,476 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $158.76 |
52-Week Low | $1.27 | $105.55 |
Typical Hold Time | 14 Days | 65 Days |
Enterprise Value | -$1.49M | $102.12B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.52, up 1.67% with a bearish technical outlook despite recent earnings beats. The company shows no revenue but has improved quarterly EPS performance, with Q4 2025 turning positive. Analyst sentiment is bullish with 75% buy ratings, while technical indicators show selling pressure with 15 sell signals versus 1 buy.
Investment outlook remains speculative given negative profitability metrics and zero revenue, though patent developments and FDA guidance provide potential catalysts. Key risks include cash burn and clinical trial outcomes, while institutional support through financing offers near-term stability.
Johnson Controls (JCI) trades at $154.00, down 1.24% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q3 2026 EPS of $1.42 beating expectations by 9.2% and raising full-year guidance. Revenue trends show recovery from $23.0B in 2024 to $23.6B in 2025, with net income margin expanding significantly to 13.94%. Recent news highlights strong demand for data-center thermal management systems and inclusion in AI industrial stock recommendations.
JCI presents a compelling investment case with 62% analyst buy ratings and $172.50 consensus price target offering 12% upside. The company benefits from strong AI-driven demand in thermal management systems, though elevated P/E of 43.38 and debt-to-asset ratio increasing to 26.06% warrant monitoring. Execution on raised FY26 guidance and data-center market expansion remain key catalysts for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
